Please login to the form below

Not currently logged in
Email:
Password:

cervical cancer

This page shows the latest cervical cancer news and features for those working in and with pharma, biotech and healthcare.

GSK eyes follow-up HPV vaccine

GSK eyes follow-up HPV vaccine

Innovax has already developed a cervical cancer vaccine, Cecolin, which is HPV 16 &18 bivalent – these two HPV types are known to cause at least 70% of cervical cancers. ... Under the agreement, Innovax said it and GSK “will continuously support the

Latest news

  • Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

    Cases of the skin cancer are increasing in certain European countries, there is little on the market for those suffering with advanced stages of the disease. ... cell carcinoma and cervical cancer.

  • Iovance up on good ASCO abstract data for cervical cancer therapy Iovance up on good ASCO abstract data for cervical cancer therapy

    The headline news is data from the cervical cancer trial of LN-145, which revealed an overall response rate (ORR) of 44% in recurrent cervical cancer, with 89% of patients showing ... That compares very well with results seen with Merck &Co’s PD-1

  • Advaxis shaken by another FDA hold on cervical cancer vaccine Advaxis shaken by another FDA hold on cervical cancer vaccine

    Suspends enrolment into pivotal phase 3 trial. Advaxis shares have fallen after the FDA placed a partial hold on its lead cancer vaccine axalimogene filolisbac (Axal). ... One of those trials involved a combination of Axal with AstraZeneca’s PD-L1

  • Artificial intelligence in healthcare Artificial intelligence in healthcare

    AI is already being used to identify women whose Twitter posts indicate may have increased risk of developing ovarian and cervical cancer, and earlier this year the UK launched a project ... The aim is to spot at least 50, 000 cases of prostate, ovarian,

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    cancer (NSCLC), an indication which is fast becoming the main battleground for the PD-1/PD-L1 class and at the moment is dominated by Keytruda. ... which none of the first five PD-1/PD-L1 drugs have been approved, as well as cervical cancer.

More from news
Approximately 9 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The approach is however also set to be tested as an in vivo therapy for cervical cancer caused by human papillomavirus (HPV) by researchers in China,

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Immunisation politicised Immunisation politicised

    human papilloma virus (HPV), including strains that lead to cervical cancer. ... Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine Pharmaceuticals. Combination clinical trials. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Country report: The healthcare market in Brazil Country report: The healthcare market in Brazil

    In September 2011, the government announced the funding of programmes that prevent, diagnose and treat cervical and breast cancer. ... AIDS, cancer, diabetes and less common conditions such as Chagas disease and endometriosis, covering around 400, 000

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics